Assenagon Asset Management S.A. 13F: Adds $375M to AMGN Stake

Assenagon Asset Management has significantly raised its investment in Amgen Inc. (NasdaqGS: AMGN), according to a Form 13F filing with the SEC. Institutional reports like these are backward-looking and show holdings as of the end of the reporting quarter, meaning they may not represent the fund's exact current position today.

What Changed in Assenagon Asset Management's Amgen Position

Assenagon Asset Management lifted its stake in the drug maker by a dramatic 464.7% during the period. The fund added 888,819 shares to its portfolio, ending with a total of 1,080,066 shares. That larger stake was valued at $455,258,620 at the time of the report, a substantial step up from the 191,247 shares held previously.

Other Institutional Activity in Amgen

Blackrock Inc. grew its holdings by 2,260,856 shares, ending with 49,362,016 shares worth about $21,348,577,817. Vanguard Capital Management LLC grew its holdings by 234,604 shares, ending with 35,250,101 shares worth about $15,245,315,837. State Street Corporation grew its holdings by 12,219 shares, ending with 30,560,537 shares worth about $13,217,126,348. Capital World Investors reduced its holdings by 213,811 shares, ending with 29,075,329 shares worth about $12,574,788,755. Invesco Ltd. grew its holdings by 435,254 shares, ending with 16,320,446 shares worth about $7,058,429,531.

Amgen Inc. Stock Up 1.4%

Amgen shares recently traded around $432.06. That puts the stock about 4.2% above its 50-day moving average and 17.3% higher than its 200-day moving average. The stock sits slightly below its 52-week high of $447.03.

Recent Earnings

Amgen posted trailing twelve-month revenue of $38.09 billion alongside basic earnings per share of $16.10. The company generated a net profit margin of 23.0% and a return on equity of 91.5%. Its next financial update is scheduled for November 3, 2026.

Dividend

Amgen currently pays an annual dividend yielding 2.32%, supported by a payout ratio of 60.9%.

Insider Buying and Selling at Amgen Inc.

Company insiders trimmed portions of their stock ahead of the filing period. Officer Nancy A. Grygiel sold 2,970 shares on August 6, 2026, at an average price of $402.16 for a total value of $1,194,415. Officer Derek Miller sold 3,890 shares on the same day at an average price of $402.54, totaling $1,565,898. Later, on August 13, 2026, officer Rachna Khosla sold 3,252 shares valued at $1,346,499.

Analysts Set New Price Targets

Wall Street firms have kept a close eye on the drug maker. On October 8, 2026, RBC Capital maintained its Outperform rating and raised its price target from $400.00 to $430.00. UBS maintained a Buy rating on October 9, 2026, lifting its target from $430.00 to $470.00. BMO Capital maintained a Market Perform rating on October 12, 2026, while lowering its target from $450.00 to $415.00. On the same day, Wells Fargo maintained an Equal-Weight rating and adjusted its target from $435.00 to $430.00. Guggenheim maintained a Neutral rating on October 13, 2026, reducing its target from $388.00 to $378.00.

About Amgen

Based in Thousand Oaks, California, Amgen researches, develops, and manufactures human therapeutics to treat serious illnesses across multiple medical fields. The firm's portfolio includes treatments in oncology, inflammation, and cardiovascular disease, making its pipeline a focal point for institutional investors tracking the healthcare sector.

Bottom Line

Assenagon Asset Management's sizable addition reflects strong interest in Amgen's pipeline and market position. Observers will look toward the company's upcoming earnings report on November 3, 2026, for further insight into financial performance and operational updates.